Open | $32.460 |
Close | $32.460 |
Volume / Avg. | 3.468M / 3.766M |
Day Range | 32.450 - 32.480 |
52 Wk Range | 7.261 - 32.470 |
Market Cap | $3.727B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 81 |
Short Interest | 8.42% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of CymaBay Therapeutics (NASDAQ: CBAY) through any online brokerage.
Other companies in CymaBay Therapeutics’s space includes: Novo Nordisk (NYSE:NVO), Merck & Co (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for CymaBay Therapeutics (NASDAQ: CBAY) was reported by HC Wainwright & Co. on Thursday, February 29, 2024. The analyst firm set a price target for 32.50 expecting CBAY to rise to within 12 months (a possible 0.09% upside). 42 analyst firms have reported ratings in the last year.
The stock price for CymaBay Therapeutics (NASDAQ: CBAY) is $32.47 last updated March 18, 2024 at 7:49 PM EDT.
There are no upcoming dividends for CymaBay Therapeutics.
CymaBay Therapeutics’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for CymaBay Therapeutics.
CymaBay Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.